loratadine has been researched along with Chronic Disease in 56 studies
Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.
loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Desloratadine citrate disodium can effectively reduce the severity of chronic urticaria, and its therapeutic mechanism may be related to balancing Th1/Th2 cell function, regulating inflammatory mediators and inhibiting the action of chemokines." | 9.30 | Effects of Desloratadine Citrate Disodium on Serum Immune Function Indices, Inflammatory Factors and Chemokines in Patients with Chronic Urticaria. ( Wang, J; Yan, X; Zhao, Y, 2019) |
| "Desloratadine citrate disodium treatment effect of chronic urticaria is better, and after treatment, IL4, IL18, IL23, IL33 levels decreased significantly." | 9.24 | Clinical observation on the therapeutic effect of desloratadine citrate disodium in the treatment of chronic urticaria and changes in IL4, IL18, IL23 and IL-33 levels before and after treatment. ( Yang, X; Zheng, D, 2017) |
| "Rupatadine is effective and well tolerated in the relief of urticaria symptoms, improving quality of life over 6 weeks in children with CSU." | 9.22 | Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years. ( Barkai, L; Izquierdo, I; Maurer, M; Mezei, G; Mitha, E; Potter, P; Santamaría, E, 2016) |
| "Levocetirizine led to a significantly greater decrease in pruritus severity than desloratadine over the first treatment week; mean pruritus severity scores of 1." | 9.14 | Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. ( Finlay, AY; Guillet, G; Hauptmann, P; Jian, AM; Kapp, A; Maurer, M; Potter, PC, 2009) |
| "Loratadine added to montelukast has been suggested to improve endpoints of asthma." | 9.14 | A randomized study comparing the effect of loratadine added to montelukast with montelukast, loratadine, and beclomethasone monotherapies in patients with chronic asthma. ( Dass, SB; Liu, N; Lu, S; Reiss, TF, 2009) |
| "Increasing the dosage of levocetirizine and desloratadine up to 4-fold improves chronic urticaria symptoms without compromising safety in approximately three quarters of patients with difficult-to-treat chronic urticaria." | 9.14 | The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. ( Church, DS; Church, MK; Dimitrov, V; Kraeva, S; Kralimarkova, T; Lazarova, C; Popov, TA; Popova, D; Staevska, M, 2010) |
| "To assess the effect of desloratadine on quality of life (QoL) in chronic idiopathic urticaria (CIU)." | 9.13 | Quality of life in adults with chronic idiopathic urticaria receiving desloratadine: a randomized, double-blind, multicentre, placebo-controlled study. ( Auquier, P; Dreyfus, I; Grob, JJ; Ortonne, JP, 2008) |
| "Assess the effect of desloratadine 5 mg once daily on the quality of life of patients suffering of chronic idiopathic urticaria (CIU)." | 9.12 | Desloratadine 5 mg once daily improves the quality of life of patients with chronic idiopathic urticaria. ( Boonen, H; De Swerdt, A; Decroix, J; Henrijean, A; Lachapelle, JM; Lecuyer, M; Roquet-Gravy, PP; Speelman, G; Suys, E; Vastesaeger, N, 2006) |
| "Once-daily desloratadine 5mg is well tolerated and superior to placebo in reducing pruritus and wheals associated with CIU." | 9.12 | Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial. ( Auquier, P; Dreyfus, I; Grob, JJ; Ortonne, JP, 2007) |
| "The aim of this study is to determine whether montelukast, a LTD4 receptor antagonist, plus desloratadine, is more efficacious than desloratadine alone in the treatment of chronic urticaria." | 9.11 | Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. ( Colanardi, MC; Ferrannini, A; Nettis, E; Paradiso, MT, 2004) |
| "Compared with placebo, desloratadine significantly improved the total CIU symptom score as well as pruritus, the number of hives, and the size of the largest hive." | 9.10 | Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. ( Bernstein, D; Finn, A; Guerrero, R; Monroe, E; Patel, P; Ratner, P, 2003) |
| "Mizolastine is a novel histamine H1-antagonist registered in Europe for the management of allergic rhinitis and urticaria." | 9.09 | Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study. ( Dubertret, L; Murrieta Aguttes, M; Tonet, J, 1999) |
| "To determine whether montelukast plus loratadine provides improved efficacy to montelukast alone in the treatment of chronic asthma." | 9.09 | Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma. ( Finn, AF; Geissler, L; Nguyen, H; Peszek, I; Reicin, A; Seidenberg, BC; Weinstein, SF; White, R, 2000) |
| "Desloratadine was superior to placebo in controlling pruritus and total symptoms after the first dose and maintained this superiority to the end of the study." | 9.09 | Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. ( Bronsky, E; Gauger, A; Hein, R; Miller, B; Ring, J, 2001) |
| "The H1 antihistamine loratadine reduces cough induced by UNDW." | 9.08 | Effect of loratadine, an H1 antihistamine, on induced cough in non-asthmatic patients with chronic cough. ( Hirata, K; Kurihara, N; Takeda, T; Tanaka, S; Yoshikawa, J, 1996) |
| " Desloratadine therapy significantly reduced nasal and ocular symptom severity, itching and wheals, and sleep and activity disruption (p < 0." | 8.86 | Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. ( Bachert, C; Maurer, M, 2010) |
| "To demonstrate the treatment outcomes and dose reduction in desloratadine assessed using the urticarial activity score over 7 consecutive days." | 7.88 | The treatment outcomes and dose de-escalation of desloratadine up-dosing in chronic spontaneous urticaria. ( Chaowattanapanit, S; Choonhakarn, C; Julanon, N, 2018) |
| "H1-receptor inhibiting drugs, namely loratadine and cetirizine, were frequently used in treatment of chronic urticaria." | 7.80 | Effects of loratadine and cetirizine on serum levels of neuropeptides in patients with chronic urticaria. ( Başak, PY; Buyukbayram, HI; Erturan, I; Kazanoglu, OO; Vural, H, 2014) |
| " Desloratadine, a non-sedating, second-generation H(1)-receptor antagonist, is an effective and well-tolerated treatment for chronic idiopathic urticaria (CIU)." | 7.75 | Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: an observational study of 9246 patients. ( Augustin, M; Ehrle, S, 2009) |
| "The effects of one week's daily treatment with dexchlorpheniramine (3 + 3 mg x 2) and loratadine (10 mg x 2) on the cutaneous reactions to putative mediators of urticarial reactions were studied in healthy subjects and in patients with chronic urticaria." | 7.68 | Effects of antihistamines on cutaneous reactions and influx of eosinophils after local injection of PAF, kallikrein, compound 48/80 and histamine in patients with chronic urticaria and healthy subjects. ( Juhlin, L; Pihl-Lundin, I, 1992) |
| " The efficiency and side-effect were evaluated at the end of treatment." | 6.73 | Efficacy and safety of desloratadine combined with dipyridamole in the treatment of chronic urticaria. ( Abdalla, AN; Khalaf, AT; Liu, XM; Sheng, WX; Tan, JQ, 2008) |
| "Treatment with desloratadine caused a relevant reduction of ROS levels and SOD activity (P<0." | 6.72 | Influence of desloratadine on oxidative stress markers in patients with chronic idiopathic urticaria. ( Amoruso, A; Cassano, N; D'Argento, V; Filieri, M; Filotico, R; Raho, G; Vena, GA, 2006) |
| "Loratadine is a new selective peripheral histamine H1-receptor antagonist, that is orally effective, long-acting, and devoid of significant central and autonomic nervous system activity." | 6.67 | Comparative effects of loratadine and terfenadine in the treatment of chronic idiopathic urticaria. ( Belaich, S; Bruttmann, G; DeGreef, H; Lachapelle, JM; Paul, E; Pedrali, P; Tennstedt, D, 1990) |
| " Loratadine was safe and well tolerated with sedation and dry mouth similar to placebo and significantly less than hydroxyzine." | 6.67 | Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria. ( Bernstein, DI; Cuss, F; Danzig, MR; Fox, RW; Garvin, PR; Grabiec, SV; Honsinger, RW; Kalivas, JT; Katz, HI; Monroe, EW, 1992) |
| " Age and sex have no apparent effect on the drug's metabolism and elimination, and food does not affect its bioavailability or absorption." | 6.44 | Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy. ( DuBuske, L, 2007) |
| "Desloratadine is a once-daily, non-sedating, non-impairing, selective histamine H1-receptor antagonist." | 6.43 | Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders. ( DuBuske, LM, 2005) |
| "Desloratadine is a novel, potent H1-receptor antagonist with additional inhibitory effects on inflammatory mediators such as cytokines and adhesion molecules." | 6.41 | Desloratadine in the treatment of chronic idiopathic urticaria. ( Gauger, A; Hein, R; Ring, J, 2001) |
| "H1 nonsedating antihistamines, such as desloratadine, are first-line treatment options for chronic spontaneous urticaria (CSU)." | 5.34 | Human H1 receptor (HRH1) gene polymorphism is associated with the severity of side effects after desloratadine treatment in Chinese patients with chronic spontaneous uticaria. ( Chen, W; Chen, X; Li, J; Liu, Z; Peng, C; Su, J; Zhang, W; Zhu, W, 2020) |
| "Desloratadine citrate disodium can effectively reduce the severity of chronic urticaria, and its therapeutic mechanism may be related to balancing Th1/Th2 cell function, regulating inflammatory mediators and inhibiting the action of chemokines." | 5.30 | Effects of Desloratadine Citrate Disodium on Serum Immune Function Indices, Inflammatory Factors and Chemokines in Patients with Chronic Urticaria. ( Wang, J; Yan, X; Zhao, Y, 2019) |
| "Desloratadine citrate disodium treatment effect of chronic urticaria is better, and after treatment, IL4, IL18, IL23, IL33 levels decreased significantly." | 5.24 | Clinical observation on the therapeutic effect of desloratadine citrate disodium in the treatment of chronic urticaria and changes in IL4, IL18, IL23 and IL-33 levels before and after treatment. ( Yang, X; Zheng, D, 2017) |
| "Rupatadine is effective and well tolerated in the relief of urticaria symptoms, improving quality of life over 6 weeks in children with CSU." | 5.22 | Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years. ( Barkai, L; Izquierdo, I; Maurer, M; Mezei, G; Mitha, E; Potter, P; Santamaría, E, 2016) |
| "Levocetirizine led to a significantly greater decrease in pruritus severity than desloratadine over the first treatment week; mean pruritus severity scores of 1." | 5.14 | Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. ( Finlay, AY; Guillet, G; Hauptmann, P; Jian, AM; Kapp, A; Maurer, M; Potter, PC, 2009) |
| "Increasing the dosage of levocetirizine and desloratadine up to 4-fold improves chronic urticaria symptoms without compromising safety in approximately three quarters of patients with difficult-to-treat chronic urticaria." | 5.14 | The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. ( Church, DS; Church, MK; Dimitrov, V; Kraeva, S; Kralimarkova, T; Lazarova, C; Popov, TA; Popova, D; Staevska, M, 2010) |
| "Loratadine added to montelukast has been suggested to improve endpoints of asthma." | 5.14 | A randomized study comparing the effect of loratadine added to montelukast with montelukast, loratadine, and beclomethasone monotherapies in patients with chronic asthma. ( Dass, SB; Liu, N; Lu, S; Reiss, TF, 2009) |
| "To assess the effect of desloratadine on quality of life (QoL) in chronic idiopathic urticaria (CIU)." | 5.13 | Quality of life in adults with chronic idiopathic urticaria receiving desloratadine: a randomized, double-blind, multicentre, placebo-controlled study. ( Auquier, P; Dreyfus, I; Grob, JJ; Ortonne, JP, 2008) |
| "Assess the effect of desloratadine 5 mg once daily on the quality of life of patients suffering of chronic idiopathic urticaria (CIU)." | 5.12 | Desloratadine 5 mg once daily improves the quality of life of patients with chronic idiopathic urticaria. ( Boonen, H; De Swerdt, A; Decroix, J; Henrijean, A; Lachapelle, JM; Lecuyer, M; Roquet-Gravy, PP; Speelman, G; Suys, E; Vastesaeger, N, 2006) |
| "Once-daily desloratadine 5mg is well tolerated and superior to placebo in reducing pruritus and wheals associated with CIU." | 5.12 | Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial. ( Auquier, P; Dreyfus, I; Grob, JJ; Ortonne, JP, 2007) |
| "The aim of this study is to determine whether montelukast, a LTD4 receptor antagonist, plus desloratadine, is more efficacious than desloratadine alone in the treatment of chronic urticaria." | 5.11 | Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. ( Colanardi, MC; Ferrannini, A; Nettis, E; Paradiso, MT, 2004) |
| "Compared with placebo, desloratadine significantly improved the total CIU symptom score as well as pruritus, the number of hives, and the size of the largest hive." | 5.10 | Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. ( Bernstein, D; Finn, A; Guerrero, R; Monroe, E; Patel, P; Ratner, P, 2003) |
| "To determine whether montelukast plus loratadine provides improved efficacy to montelukast alone in the treatment of chronic asthma." | 5.09 | Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma. ( Finn, AF; Geissler, L; Nguyen, H; Peszek, I; Reicin, A; Seidenberg, BC; Weinstein, SF; White, R, 2000) |
| "Mizolastine is a novel histamine H1-antagonist registered in Europe for the management of allergic rhinitis and urticaria." | 5.09 | Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study. ( Dubertret, L; Murrieta Aguttes, M; Tonet, J, 1999) |
| "Desloratadine was superior to placebo in controlling pruritus and total symptoms after the first dose and maintained this superiority to the end of the study." | 5.09 | Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. ( Bronsky, E; Gauger, A; Hein, R; Miller, B; Ring, J, 2001) |
| "The H1 antihistamine loratadine reduces cough induced by UNDW." | 5.08 | Effect of loratadine, an H1 antihistamine, on induced cough in non-asthmatic patients with chronic cough. ( Hirata, K; Kurihara, N; Takeda, T; Tanaka, S; Yoshikawa, J, 1996) |
| " Desloratadine therapy significantly reduced nasal and ocular symptom severity, itching and wheals, and sleep and activity disruption (p < 0." | 4.86 | Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. ( Bachert, C; Maurer, M, 2010) |
| "To demonstrate the treatment outcomes and dose reduction in desloratadine assessed using the urticarial activity score over 7 consecutive days." | 3.88 | The treatment outcomes and dose de-escalation of desloratadine up-dosing in chronic spontaneous urticaria. ( Chaowattanapanit, S; Choonhakarn, C; Julanon, N, 2018) |
| "H1-receptor inhibiting drugs, namely loratadine and cetirizine, were frequently used in treatment of chronic urticaria." | 3.80 | Effects of loratadine and cetirizine on serum levels of neuropeptides in patients with chronic urticaria. ( Başak, PY; Buyukbayram, HI; Erturan, I; Kazanoglu, OO; Vural, H, 2014) |
| " Systemic mastocytosis and other causes of chronic diarrhea, especially therapy with methotrexate, were carefully ruled out." | 3.77 | Mastocytic enterocolitis as a rare cause of chronic diarrhea in a patient with rheumatoid arthritis. ( Langner, C; Siegel, C; Thonhofer, R; Trummer, M, 2011) |
| " Desloratadine, a non-sedating, second-generation H(1)-receptor antagonist, is an effective and well-tolerated treatment for chronic idiopathic urticaria (CIU)." | 3.75 | Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: an observational study of 9246 patients. ( Augustin, M; Ehrle, S, 2009) |
| "The effects of one week's daily treatment with dexchlorpheniramine (3 + 3 mg x 2) and loratadine (10 mg x 2) on the cutaneous reactions to putative mediators of urticarial reactions were studied in healthy subjects and in patients with chronic urticaria." | 3.68 | Effects of antihistamines on cutaneous reactions and influx of eosinophils after local injection of PAF, kallikrein, compound 48/80 and histamine in patients with chronic urticaria and healthy subjects. ( Juhlin, L; Pihl-Lundin, I, 1992) |
| " The efficiency and side-effect were evaluated at the end of treatment." | 2.73 | Efficacy and safety of desloratadine combined with dipyridamole in the treatment of chronic urticaria. ( Abdalla, AN; Khalaf, AT; Liu, XM; Sheng, WX; Tan, JQ, 2008) |
| "Treatment with desloratadine caused a relevant reduction of ROS levels and SOD activity (P<0." | 2.72 | Influence of desloratadine on oxidative stress markers in patients with chronic idiopathic urticaria. ( Amoruso, A; Cassano, N; D'Argento, V; Filieri, M; Filotico, R; Raho, G; Vena, GA, 2006) |
| "Loratadine was safe and well tolerated." | 2.67 | Comparative study of the efficacy and safety of loratadine syrup and terfenadine suspension in the treatment of chronic allergic skin diseases in a pediatric population. ( Cerio, R; Chieira, ML; deGroot, LJ; Giannetti, A; Gonçalves, HM; Guillot, B; Lutsky, BN; Lynde, CW; Schuller, JL; Vareltzides, A, 1993) |
| " Loratadine was safe and well tolerated with sedation and dry mouth similar to placebo and significantly less than hydroxyzine." | 2.67 | Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria. ( Bernstein, DI; Cuss, F; Danzig, MR; Fox, RW; Garvin, PR; Grabiec, SV; Honsinger, RW; Kalivas, JT; Katz, HI; Monroe, EW, 1992) |
| "Loratadine is a new selective peripheral histamine H1-receptor antagonist, that is orally effective, long-acting, and devoid of significant central and autonomic nervous system activity." | 2.67 | Comparative effects of loratadine and terfenadine in the treatment of chronic idiopathic urticaria. ( Belaich, S; Bruttmann, G; DeGreef, H; Lachapelle, JM; Paul, E; Pedrali, P; Tennstedt, D, 1990) |
| " Age and sex have no apparent effect on the drug's metabolism and elimination, and food does not affect its bioavailability or absorption." | 2.44 | Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy. ( DuBuske, L, 2007) |
| "Desloratadine is a once-daily, non-sedating, non-impairing, selective histamine H1-receptor antagonist." | 2.43 | Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders. ( DuBuske, LM, 2005) |
| "Desloratadine is a novel, potent H1-receptor antagonist with additional inhibitory effects on inflammatory mediators such as cytokines and adhesion molecules." | 2.41 | Desloratadine in the treatment of chronic idiopathic urticaria. ( Gauger, A; Hein, R; Ring, J, 2001) |
| "Chronic urticaria is a common dermatologic condition that is idiopathic in most cases." | 2.41 | Desloratidine for the treatment of chronic urticaria. ( Monroe, EW, 2002) |
| " Patients could be categorized into four groups based on the results of ASST and SPT to HDM and patients with positive ASST and positive SPT to HDM had the highest disease activity scores, experienced higher frequencies of angioedema, diseases duration, and required higher dosage of loratadine every month, compared with other subgroups (P<0." | 1.39 | Evaluation of autologous serum skin test and skin prick test reactivity to house dust mite in patients with chronic spontaneous urticaria. ( Chen, W; Hao, F; Song, Z; Zhai, Z; Zhong, H; Zhou, Z, 2013) |
| "The dermatitis is characterized by redness, hairloss, scaling, pruritus and histologically by epithelial hyperproliferation, infiltration of eosinophils, macrophages and mast cells." | 1.31 | Therapeutic interventions in mice with chronic proliferative dermatitis (cpdm/cpdm). ( Bruijnzeel, PL; Elliott, GR; Gijbels, MJ; HogenEsch, H; van den Hoven, A; Zurcher, C, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.79) | 18.7374 |
| 1990's | 9 (16.07) | 18.2507 |
| 2000's | 23 (41.07) | 29.6817 |
| 2010's | 22 (39.29) | 24.3611 |
| 2020's | 1 (1.79) | 2.80 |
| Authors | Studies |
|---|---|
| Li, J | 5 |
| Chen, W | 5 |
| Peng, C | 3 |
| Zhu, W | 4 |
| Liu, Z | 4 |
| Zhang, W | 3 |
| Su, J | 4 |
| Chen, X | 6 |
| Maouia, A | 1 |
| Youssef, M | 1 |
| Leban, N | 1 |
| Ben Chibani, J | 1 |
| Helal, AN | 1 |
| Kassab, A | 1 |
| Zheng, D | 1 |
| Yang, X | 1 |
| Choonhakarn, C | 1 |
| Chaowattanapanit, S | 1 |
| Julanon, N | 1 |
| Yan, J | 1 |
| Li, Q | 2 |
| Luo, Y | 1 |
| Yan, S | 4 |
| He, Y | 3 |
| Chen, M | 3 |
| Zhang, J | 3 |
| Li, F | 1 |
| Wang, J | 1 |
| Zhao, Y | 2 |
| Yan, X | 1 |
| Song, Z | 1 |
| Zhai, Z | 1 |
| Zhong, H | 1 |
| Zhou, Z | 1 |
| Hao, F | 1 |
| Leiva-Salinas, M | 1 |
| Francés, L | 1 |
| Marin-Cabanas, I | 1 |
| Arribas Granados, MP | 1 |
| Silvestre, JF | 1 |
| Başak, PY | 1 |
| Vural, H | 1 |
| Kazanoglu, OO | 1 |
| Erturan, I | 1 |
| Buyukbayram, HI | 1 |
| Wen, S | 1 |
| Guo, A | 2 |
| Zhang, C | 1 |
| Zhou, H | 1 |
| Zeng, W | 2 |
| Potter, P | 1 |
| Mitha, E | 1 |
| Barkai, L | 1 |
| Mezei, G | 1 |
| Santamaría, E | 1 |
| Izquierdo, I | 1 |
| Maurer, M | 3 |
| Kennedy, DW | 1 |
| Raison-Peyron, N | 1 |
| Reymann, V | 1 |
| Bessis, D | 1 |
| Bin, L | 1 |
| Yi, M | 1 |
| Leung, DY | 1 |
| Ciebiada, M | 1 |
| Ciebiada, MG | 1 |
| Kmiecik, T | 1 |
| DuBuske, LM | 2 |
| Gorski, P | 1 |
| Potter, PC | 1 |
| Kapp, A | 1 |
| Guillet, G | 1 |
| Jian, AM | 1 |
| Hauptmann, P | 1 |
| Finlay, AY | 1 |
| Grob, JJ | 3 |
| Auquier, P | 3 |
| Dreyfus, I | 3 |
| Ortonne, JP | 3 |
| Augustin, M | 1 |
| Ehrle, S | 1 |
| Lu, S | 1 |
| Liu, N | 1 |
| Dass, SB | 1 |
| Reiss, TF | 1 |
| Kiyici, S | 1 |
| Gul, OO | 1 |
| Baskan, EB | 1 |
| Hacioglu, S | 1 |
| Budak, F | 1 |
| Erturk, E | 1 |
| Imamoglu, S | 1 |
| Bachert, C | 1 |
| Staevska, M | 1 |
| Popov, TA | 1 |
| Kralimarkova, T | 1 |
| Lazarova, C | 1 |
| Kraeva, S | 1 |
| Popova, D | 1 |
| Church, DS | 1 |
| Dimitrov, V | 1 |
| Church, MK | 1 |
| Bérard, F | 1 |
| Boulinguez, S | 1 |
| Korkmaz, H | 1 |
| Eigelshoven, S | 1 |
| Homey, B | 1 |
| Hong, JB | 2 |
| Lee, HC | 2 |
| Hu, FC | 1 |
| Chu, CY | 2 |
| Thonhofer, R | 1 |
| Siegel, C | 1 |
| Trummer, M | 1 |
| Langner, C | 1 |
| Monroe, EW | 3 |
| Grattan, CE | 1 |
| Dawn, G | 1 |
| Gibbs, S | 1 |
| Francis, DM | 1 |
| Monroe, E | 1 |
| Finn, A | 1 |
| Patel, P | 1 |
| Guerrero, R | 1 |
| Ratner, P | 1 |
| Bernstein, D | 1 |
| Nettis, E | 1 |
| Colanardi, MC | 1 |
| Paradiso, MT | 1 |
| Ferrannini, A | 1 |
| Di Lorenzo, G | 1 |
| Pacor, ML | 1 |
| Mansueto, P | 1 |
| Esposito Pellitteri, M | 1 |
| Lo Bianco, C | 1 |
| Ditta, V | 1 |
| Martinelli, N | 1 |
| Rini, GB | 1 |
| Rottem, M | 1 |
| Elbirt, D | 1 |
| Sthoeger, Z | 1 |
| Lachapelle, JM | 2 |
| Decroix, J | 1 |
| Henrijean, A | 1 |
| Roquet-Gravy, PP | 1 |
| De Swerdt, A | 1 |
| Boonen, H | 1 |
| Lecuyer, M | 1 |
| Suys, E | 1 |
| Speelman, G | 1 |
| Vastesaeger, N | 1 |
| Cassano, N | 1 |
| Raho, G | 1 |
| Filieri, M | 1 |
| D'Argento, V | 1 |
| Amoruso, A | 1 |
| Filotico, R | 1 |
| Vena, GA | 1 |
| Lam, HC | 1 |
| Tong, MC | 1 |
| Van Hasselt, CA | 1 |
| DuBuske, L | 1 |
| Khalaf, AT | 1 |
| Liu, XM | 1 |
| Sheng, WX | 1 |
| Tan, JQ | 1 |
| Abdalla, AN | 1 |
| Lutsky, BN | 1 |
| Schuller, JL | 1 |
| Cerio, R | 1 |
| Chieira, ML | 1 |
| Giannetti, A | 1 |
| Gonçalves, HM | 1 |
| deGroot, LJ | 1 |
| Vareltzides, A | 1 |
| Guillot, B | 1 |
| Lynde, CW | 1 |
| Tanaka, S | 1 |
| Hirata, K | 1 |
| Kurihara, N | 1 |
| Yoshikawa, J | 1 |
| Takeda, T | 1 |
| Goriachkina, LA | 1 |
| Peredkova, EV | 1 |
| Dubertret, L | 1 |
| Murrieta Aguttes, M | 1 |
| Tonet, J | 1 |
| Reicin, A | 1 |
| White, R | 1 |
| Weinstein, SF | 1 |
| Finn, AF | 1 |
| Nguyen, H | 1 |
| Peszek, I | 1 |
| Geissler, L | 1 |
| Seidenberg, BC | 1 |
| Gijbels, MJ | 1 |
| Elliott, GR | 1 |
| HogenEsch, H | 1 |
| Zurcher, C | 1 |
| van den Hoven, A | 1 |
| Bruijnzeel, PL | 1 |
| Ring, J | 2 |
| Hein, R | 2 |
| Gauger, A | 2 |
| Bronsky, E | 1 |
| Miller, B | 1 |
| Juhlin, L | 1 |
| Pihl-Lundin, I | 1 |
| Bernstein, DI | 2 |
| Fox, RW | 2 |
| Grabiec, SV | 1 |
| Honsinger, RW | 1 |
| Kalivas, JT | 1 |
| Katz, HI | 1 |
| Cuss, F | 1 |
| Danzig, MR | 1 |
| Garvin, PR | 1 |
| Abu Shareeah, AM | 1 |
| Pedersen, MF | 1 |
| Belaich, S | 1 |
| Bruttmann, G | 1 |
| DeGreef, H | 1 |
| Paul, E | 1 |
| Pedrali, P | 1 |
| Tennstedt, D | 1 |
| Green, AW | 1 |
| Izuno, GT | 1 |
| Pleskow, WW | 1 |
| Willis, I | 1 |
| Brigante, JR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "A Pilot, Multicenter, Double-blind Randomized Study for Comparison of Aerius® Continuous Treatment Versus Aerius® PRN Regimen on Chronic Idiopathic Urticaria Patient Quality of Life"[NCT00783354] | Phase 4 | 129 participants (Actual) | Interventional | 2003-04-01 | Completed | ||
| Aprepitant vs. Desloratadine in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Related Pruritus: A Prospective, Randomized Control, Double-blinded, Phase II Clinical Trial[NCT02646020] | Phase 2 | 138 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Efficacy and Safety of 20 mg Levocetirizine and 15 mg Levocetirizine + 50 mg Bed-Time Hydroxyzine in Severe Chronic Urticaria in Adults: a Pilot, Randomized, Double-blind, Cross-over and Parallel, Active-controlled, Single-centre Study[NCT01250652] | Phase 4 | 24 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for loratadine and Chronic Disease
| Article | Year |
|---|---|
Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies.
Topics: Activities of Daily Living; Adult; Anti-Allergic Agents; Chronic Disease; Female; Germany; Histamine | 2010 |
[Diagnostic and physiopathological innovations related to chronic urticaria].
Topics: Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Autoantibodie | 2010 |
Desloratidine for the treatment of chronic urticaria.
Topics: Chronic Disease; Histamine H1 Antagonists; Humans; Loratadine; Urticaria | 2002 |
Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders.
Topics: Adult; Aged; Animals; Anti-Inflammatory Agents; Asthma; Child; Child, Preschool; Chronic Disease; Cl | 2005 |
Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy.
Topics: Acetates; Adolescent; Adult; Child; Chronic Disease; Cyclopropanes; Drug Therapy, Combination; Hista | 2007 |
Desloratadine in the treatment of chronic idiopathic urticaria.
Topics: Cholinergic Antagonists; Chronic Disease; Cytokines; Histamine H1 Antagonists; Humans; Loratadine; S | 2001 |
32 trials available for loratadine and Chronic Disease
| Article | Year |
|---|---|
Human H1 receptor (HRH1) gene polymorphism is associated with the severity of side effects after desloratadine treatment in Chinese patients with chronic spontaneous uticaria.
Topics: Adult; China; Chronic Disease; Drug-Related Side Effects and Adverse Reactions; Female; Histamine H1 | 2020 |
CRP relevance in clinical assessment of chronic spontaneous urticaria Tunisian patients.
Topics: Adult; Anti-Inflammatory Agents; Antioxidants; C-Reactive Protein; Catalase; Chronic Disease; Female | 2017 |
Clinical observation on the therapeutic effect of desloratadine citrate disodium in the treatment of chronic urticaria and changes in IL4, IL18, IL23 and IL-33 levels before and after treatment.
Topics: Adolescent; Adult; Chronic Disease; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Interleu | 2017 |
Effects of Desloratadine Citrate Disodium on Serum Immune Function Indices, Inflammatory Factors and Chemokines in Patients with Chronic Urticaria.
Topics: Administration, Oral; Adult; Biomarkers; Chemokine CCL5; Chemokines; China; Cholinergic Antagonists; | 2019 |
Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years.
Topics: Age Factors; Child; Child, Preschool; Chronic Disease; Cyproheptadine; Double-Blind Method; Female; | 2016 |
Quality of life in patients with persistent allergic rhinitis treated with montelukast alone or in combination with levocetirizine or desloratadine.
Topics: Acetates; Adolescent; Adult; Aged; Cetirizine; Chronic Disease; Cross-Over Studies; Cyclopropanes; D | 2008 |
Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients.
Topics: Cetirizine; Chronic Disease; Double-Blind Method; Female; Histamine H1 Antagonists, Non-Sedating; Hu | 2009 |
How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life.
Topics: Adult; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Female; Histamine H1 Anta | 2009 |
A randomized study comparing the effect of loratadine added to montelukast with montelukast, loratadine, and beclomethasone monotherapies in patients with chronic asthma.
Topics: Acetates; Adolescent; Adult; Aged; Anti-Allergic Agents; Asthma; Beclomethasone; Chronic Disease; Cr | 2009 |
Effect of levothyroxine treatment on clinical symptoms and serum cytokine levels in euthyroid patients with chronic idiopathic urticaria and thyroid autoimmunity.
Topics: Adolescent; Adult; Autoimmune Diseases; Chi-Square Distribution; Chronic Disease; Drug Combinations; | 2010 |
The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria.
Topics: Adult; Aged; Cetirizine; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Fem | 2010 |
A randomized, double-blind, active-controlled, parallel-group pilot study to compare the efficacy and sedative effects of desloratadine 5 mg with levocetirizine 5 mg in the treatment of chronic idiopathic urticaria.
Topics: Cetirizine; Chronic Disease; Double-Blind Method; Female; Histamine H1 Antagonists, Non-Sedating; Hu | 2010 |
Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Child; Chronic Disease; Double-Blind Method; Drug Administr | 2003 |
Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study.
Topics: Acetates; Administration, Oral; Adolescent; Adult; Aged; Chronic Disease; Cyclopropanes; Double-Blin | 2004 |
Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria.
Topics: Acetates; Adolescent; Adult; Aged; Chronic Disease; Cyclopropanes; Double-Blind Method; Female; Hist | 2004 |
[Desloratadine for chronic idiopathic urticaria].
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Female; Histamine H1 Antagonists, Non-Sedating; Hum | 2005 |
Desloratadine 5 mg once daily improves the quality of life of patients with chronic idiopathic urticaria.
Topics: Administration, Oral; Adult; Belgium; Chronic Disease; Drug Administration Schedule; Female; Histami | 2006 |
Influence of desloratadine on oxidative stress markers in patients with chronic idiopathic urticaria.
Topics: Adult; Aged; Biomarkers; Chronic Disease; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Lo | 2006 |
Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Adult; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Histamine H1 | 2007 |
Rhinitis symptoms and quality of life in patients with chronic perennial rhinitis treated with desloratadine.
Topics: Adult; Chronic Disease; Endoscopy; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadin | 2007 |
Efficacy and safety of desloratadine combined with dipyridamole in the treatment of chronic urticaria.
Topics: Administration, Oral; Adolescent; Adult; Aged; Child; Child, Preschool; Chronic Disease; Dipyridamol | 2008 |
Quality of life in adults with chronic idiopathic urticaria receiving desloratadine: a randomized, double-blind, multicentre, placebo-controlled study.
Topics: Activities of Daily Living; Adult; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind M | 2008 |
Comparative study of the efficacy and safety of loratadine syrup and terfenadine suspension in the treatment of chronic allergic skin diseases in a pediatric population.
Topics: Child; Chronic Disease; Dermatitis, Contact; Humans; Loratadine; Skin; Solutions; Suspensions; Terfe | 1993 |
Effect of loratadine, an H1 antihistamine, on induced cough in non-asthmatic patients with chronic cough.
Topics: Adult; Chronic Disease; Cough; Cross-Over Studies; Double-Blind Method; Female; Histamine H1 Antagon | 1996 |
[The clinical efficacy of Claritin in treating allergic diseases].
Topics: Acute Disease; Adolescent; Adult; Anti-Allergic Agents; Child; Chronic Disease; Histamine H1 Antagon | 1997 |
Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study.
Topics: Adult; Analysis of Variance; Appendicitis; Benzimidazoles; Chronic Disease; Double-Blind Method; Ele | 1999 |
Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma.
Topics: Acetates; Adolescent; Adult; Aged; Asthma; Chronic Disease; Cross-Over Studies; Cyclopropanes; Doubl | 2000 |
Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Cholinergic Antagonists; Chronic Disease; Dizziness; Double-Blind Method; D | 2001 |
Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria.
Topics: Adolescent; Adult; Aged; Chronic Disease; Double-Blind Method; Humans; Hydroxyzine; Loratadine; Midd | 1992 |
Comparative efficacy of loratadine and terfenadine in the treatment of chronic idiopathic urticaria.
Topics: Adult; Chronic Disease; Cyproheptadine; Female; Histamine Antagonists; Humans; Loratadine; Male; Pru | 1992 |
Comparative effects of loratadine and terfenadine in the treatment of chronic idiopathic urticaria.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Chronic Disease; Clinical Trials as Topic; Cyprohepta | 1990 |
Efficacy and safety of loratadine (10 mg once daily) in the management of idiopathic chronic urticaria.
Topics: Chronic Disease; Clinical Trials as Topic; Cyproheptadine; Double-Blind Method; Histamine H1 Antagon | 1988 |
18 other studies available for loratadine and Chronic Disease
| Article | Year |
|---|---|
The treatment outcomes and dose de-escalation of desloratadine up-dosing in chronic spontaneous urticaria.
Topics: Adult; Chronic Disease; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Maintena | 2018 |
[Association of CACNA1C gene genetic polymorphism with the susceptibility as well as prognosis for chronic spontaneous urticaria].
Topics: Calcium Channels, L-Type; Chronic Disease; Genetic Predisposition to Disease; Histamine H1 Antagonis | 2018 |
C-reactive protein (CRP) rs3093059C predicts poor mizolastine response in chronic spontaneous urticaria patients with elevated serum CRP level.
Topics: Adolescent; Adult; Aged; Animals; Benzimidazoles; C-Reactive Protein; China; Chronic Disease; Chroni | 2019 |
Evaluation of autologous serum skin test and skin prick test reactivity to house dust mite in patients with chronic spontaneous urticaria.
Topics: Adolescent; Adult; Age Factors; Aged; Animals; Anti-Allergic Agents; China; Chronic Disease; Female; | 2013 |
Effectiveness and safety of omalizumab in a patient with chronic urticaria and hepatitis C.
Topics: Anti-Allergic Agents; Chronic Disease; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Hist | 2015 |
Effects of loratadine and cetirizine on serum levels of neuropeptides in patients with chronic urticaria.
Topics: Adolescent; Adult; Calcitonin Gene-Related Peptide; Cetirizine; Chronic Disease; Female; Histamine H | 2014 |
Influence of component 5a receptor 1 (C5AR1) -1330T/G polymorphism on nonsedating H1-antihistamines therapy in Chinese patients with chronic spontaneous urticaria.
Topics: Adolescent; Adult; Aged; Asian People; Benzimidazoles; Case-Control Studies; China; Chronic Disease; | 2014 |
EDITORIAL.
Topics: Animals; Carcinogenesis; Chronic Disease; Diagnosis, Differential; Histamine Antagonists; Humans; Lo | 2015 |
Follicular Traction Urticaria: A New Form of Chronic Inducible Urticaria?
Topics: Administration, Oral; Biopsy; Chronic Disease; Drug Administration Schedule; Female; Hair Follicle; | 2017 |
Association of ORAI1 gene polymorphisms with chronic spontaneous urticaria and the efficacy of the nonsedating H1 antihistamine desloratadine.
Topics: Adult; Chronic Disease; Female; Genetic Association Studies; Genetic Predisposition to Disease; Geno | 2017 |
Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: an observational study of 9246 patients.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Chr | 2009 |
[Omalizumab for therapy-resistant chronic urticaria with angioedema].
Topics: Adult; Angioedema; Anti-Allergic Agents; Anti-Inflammatory Agents; Antibodies, Anti-Idiotypic; Antib | 2010 |
Chronic idiopathic urticaria in Taiwan: a clinical study of demographics, aggravating factors, laboratory findings, serum autoreactivity and treatment response.
Topics: Adolescent; Adult; Cetirizine; Chronic Disease; Female; Histamine H1 Antagonists; Humans; Loratadine | 2011 |
Mastocytic enterocolitis as a rare cause of chronic diarrhea in a patient with rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Biopsy; Chronic D | 2011 |
Blood basophil numbers in chronic ordinary urticaria and healthy controls: diurnal variation, influence of loratadine and prednisolone and relationship to disease activity.
Topics: Adult; Analysis of Variance; Anti-Inflammatory Agents; Basophils; Case-Control Studies; Chronic Dise | 2003 |
Therapeutic interventions in mice with chronic proliferative dermatitis (cpdm/cpdm).
Topics: Adrenal Cortex Hormones; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipruritics; Calcitriol | 2000 |
Effects of antihistamines on cutaneous reactions and influx of eosinophils after local injection of PAF, kallikrein, compound 48/80 and histamine in patients with chronic urticaria and healthy subjects.
Topics: Adult; Aged; Chlorpheniramine; Chronic Disease; Eosinophils; Female; Histamine; Histamine H1 Antagon | 1992 |
Computed phonetograms in adult patients with benign voice disorders before and after treatment with a nonsedating antihistamine (loratadine).
Topics: Adult; Aged; Chronic Disease; Cyproheptadine; Female; Histamine Antagonists; Humans; Laryngitis; Lor | 1991 |